PipelineReview. Business Intellegence Center

Proteins and Peptides

18 May 2021

DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke

15 May 2021

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

14 May 2021

PharmaEssentia Resubmits Application to the U.S. FDA For Ropeginterferon alfa-2b-njft to Treat Polycythemia Vera (PV)

11 May 2021

Axcella Announces Initiation of EMMPACT℠ Phase 2b Clinical Trial of AXA1125

10 May 2021

Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of CBX-12 (alphalex™-exatecan) in Advanced or Metastatic Refractory Solid Tumors

10 May 2021

Lytix Biopharma announces positive phase I data for LTX-315

7 May 2021

Inozyme Pharma Presents Preclinical Data Suggesting Utility of INZ-701 as a Potential Treatment for ABCC6 Deficiency

6 May 2021

Catalyst Biosciences Announces First Patient Dosed in Pivotal Phase 3 Registration Study of SQ MarzAA in Individuals with Hemophilia A or B with Inhibitors

6 May 2021

Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial

5 May 2021

BioLineRx Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

5 May 2021

Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes

28 April 2021

OKYO Pharma Announces Positive Data and Results in an Animal Model using Topically Administered OK-201 to Treat Neuropathic Ocular Pain

28 April 2021

Protalix BioTherapeutics and Chiesi Global Rare Diseases Receive Complete Response Letter for Pegunigalsidase Alfa from FDA

27 April 2021

Alkermes Initiates ARTISTRY-6 Trial of Nemvaleukin Alfa Monotherapy in Patients With Melanoma

26 April 2021

Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States

23 April 2021

UCB’s zilucoplan shows no relevant effect in immune-mediated necrotizing myopathy (IMNM)

22 April 2021

Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction

14 April 2021

Aquavit to Introduce A New Botulinum Toxin (DTX-021)

13 April 2021

Peptilogics Announces Successful Completion of Phase 1 Clinical Trial of PLG0206, a First-in-Class Anti-Infective Peptide Therapy

13 April 2021

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

12 April 2021

Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Bullous Pemphigoid (BP)

12 April 2021

Pieris Pharmaceuticals Presents Updated Phase 1 Monotherapy Data for 4-1BB/HER2 Bispecific Cinrebafusp Alfa and Preclinical Data for 4-1BB/PD-L1 Bispecific PRS-344/S095012 at 2021 AACR Annual Meeting

12 April 2021

Molecular Partners Shares New Preclinical Data from its AML-Focused CD3 T-Cell Engager Program, CD40 Product Candidate MP0317, and Other Novel Immuno-oncology Approaches at AACR

11 April 2021

Synthekine Presents Data at AACR Annual Meeting 2021 Demonstrating Selective IL-2 Partial Agonist, STK-012, Promotes Anti-Tumor Response without Related Toxicities

6 April 2021

Molecular Templates to Prioritize Next-Generation ETB Candidates

6 April 2021

AEON Biopharma Doses First Patient in Phase 2 Trial of ABP-450 for the Treatment of Cervical Dystonia

6 April 2021

Molecular Partners Announces First Patient Dosed in a Phase 2 Clinical Trial of Ensovibep in COVID-19 Patients

2 April 2021

Evive Biotech Submits Biologics License Application to US FDA for Ryzneuta™

30 March 2021

D&D Pharmatech Announces First Patient Dosed in Phase 1 Clinical Trial of DD01 in Obese Patients with Diabetes and NAFLD

27 March 2021

Saxenda® recommended for approval by European Medicines Agency committee for the treatment of obesity in adolescents aged 12–17 years

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

SubscribeNewsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

SubscribeNewsletter new product alert

Featured reports

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
Targeted Protein Degradation by Novel PROTACs and Molecular Glues 2020: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective
Aflibercept (Eylea) Biosimilars Pipeline Review
Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review
Report Package: Bispecific Antibodies
Cadherin 17: A target opportunity to develop effector-enhanced drug modalities
Ustekinumab (Stelara) Biosimilars Pipeline Review
CCR8-Targeted Antibody Immunotherapy Pipeline Review
PD-1 Agonists Pipeline Review
CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing